Rigontec
RNA-based immunotherapeutics for the treatment of cancer and viral diseases
Total raised
€28M
€27,850,000
Funding rounds
3
Investors
8
distinct backers
Active since
2014-09
latest 2016-08
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood20
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
- ▲ 12y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2016-09-01 | Series A | €14M | Boehringer Ingelheim Venture Fund,Forbion Capital Partners,High-Tech Gr√ºnderfonds (HTGF),MP Healthcare Venture Management,NRW.BANK,Sunstone Capital+1 more | View deal → |
| 2015-03-01 | Series A | €4.8M | Boehringer Ingelheim Venture Fund,Forbion Capital Partners,High-Tech Gr√ºnderfonds (HTGF),NRW.BANK,Sunstone Capital,Wellington Partners | View deal → |
| 2014-10-01 | Series A | €9.4M | Boehringer Ingelheim Venture Fund,High-Tech Gründerfonds,NRW.BANK,Wellington Partners | View deal → |
Investors
8Related news
Similar companies
same sector or country- Delivery Hero€7.3BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Celonis€2.1BGermany · Software